

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Recbio Technology Co., Ltd.

江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2179)

VOLUNTARY ANNOUNCEMENT

THE COMPANY'S FIRST PHASE OF MANUFACTURING FACILITY WITH A MAXIMUM ANNUAL OUTPUT OF 20 MILLION DOSES OF RECOMBINANT HPV 9-VALENT VACCINE

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that in order to meet the rapidly growing market demand for HPV 9-valent vaccines in China and the international market, after process optimization, facility upgrading and verification, the peak production capacity for the first phase of the HPV vaccine manufacturing facility of the Company will be increased to an annual output of 20 million doses of recombinant HPV 9-valent vaccine. The construction of such manufacturing facility has received technical guidance from experts of the World Health Organization (“**WHO**”). Upon completion, the facility will meet the requirements of China's Good Manufacturing Practices (GMP) and WHO prequalification (WHO PQ) to satisfy the global supply and demand gap of HPV 9-valent vaccines.

HPV 9-valent vaccines can prevent approximately 90% of cervical cancers and 90% of anal and genital warts, and are widely regarded as the most effective vaccines against HPV infections. At present, no domestic HPV 9-valent vaccine has been approved for sale in China. The Company's core product, HPV 9-valent vaccine REC603, is in phase III clinical stage, with a prominent advantage in total sample size and an advanced overall research and development progress. REC603 adopts the *H. polymorpha* expression system to achieve high-yield and stable expression of HPV virus-like particles and to make the Company's vaccine candidate more suitable for commercial production.

Shareholders and potential investors should note that the Group may not develop or market REC603 successfully and should exercise caution when dealing in the securities of the Company.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Dr. Liu Yong
Chairman

Jiangsu Province, the PRC, November 21, 2022

As at the date of this announcement, the Board comprises Dr. Liu Yong as the chairman of the Board and an executive director, Dr. Chen Jianping and Mr. Li Bu as executive directors, Dr. Hong Kunxue, Dr. Zhou Hongbin, Mr. Zhao Hui, Dr. Du Wei and Dr. Feng Tao as non-executive directors, and Mr. Liang Guodong, Dr. Xia Lijun, Professor Gao Feng and Professor Yuen Ming Fai as independent non-executive directors.